<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jesús Rojas-Jaimes</style></author><author><style face="normal" font="default" size="100%">Luis Castañeda Pelaez</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Generation of Multinucleated Giant Cells due to Leishmania (V.) braziliensis Infection</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Immunity</style></keyword><keyword><style  face="normal" font="default" size="100%">Infection</style></keyword><keyword><style  face="normal" font="default" size="100%">Leishmania (V.) braziliensis</style></keyword><keyword><style  face="normal" font="default" size="100%">Macrophage</style></keyword><keyword><style  face="normal" font="default" size="100%">Multinucleated Giant Cells</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">October 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">905-909</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background&lt;/strong&gt;: Multinucleated giant cells were first described by Langhans(MGCs), these MGCs have a role in innate immunity that includes extracellular matrix remodeling associated with granuloma formation; another function of them is to participate in the removal of cellular debris in apoptosis during certain infections. &lt;strong&gt;Objective: &lt;/strong&gt;Generate multinucleated giant cells due to &lt;em&gt;Leishmania &lt;/em&gt;(V.) braziliensis infection. &lt;strong&gt;Methods:&lt;/strong&gt; For infection macrophage/parasite ratio of 1 to 10 using the RAW 264.7-line (5 x10&lt;sup&gt;5&lt;/sup&gt;/mL) and &lt;em&gt;Leishmania &lt;/em&gt;(V.) &lt;em&gt;braziliensis &lt;/em&gt;metacyclic promastigotes (50 x105/mL) was a strain maintained in culture Schneider liquid medium, supplemented with 20% fetal bovine serum and 10 000 U/10 mg/mL penicillin streptomycin at pH 7 and 25 °C in the laboratory. Incubation was continued for 4 days, and microscopic observation at 1000X was performed at 24 hours and 96 hours, respectively. &lt;strong&gt;Results: &lt;/strong&gt;In our study an MGC conversion was observed at 96 hours (50% ± 28.2). &lt;strong&gt;Conclusions:&lt;/strong&gt; In vitro MGC model could be used to study the physiopathology of MGC generation by &lt;em&gt;Leishmania &lt;/em&gt;(V.) &lt;em&gt;braziliensis &lt;/em&gt;infection.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">905</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Jesús Rojas-Jaimes&lt;sup&gt;1,2,*&lt;/sup&gt;, Luis Castañeda Pelaez&lt;sup&gt;1&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Facultad de Ciencias de la Salud, Universidad Privada del Norte, Lima, PERÚ.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Escuela de Medicina Humana, Universidad Científica del Sur, Lima, PERÚ.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Yosua Butar Butar</style></author><author><style face="normal" font="default" size="100%">Puspa Wardhani</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Thalassemia β Major in Confirmed Covid-19 Patient: A Case Report</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Infection</style></keyword><keyword><style  face="normal" font="default" size="100%">Preventable Death</style></keyword><keyword><style  face="normal" font="default" size="100%">Thalassemia</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">445-449</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;The incidence of Thalassemia with confirmed Covid 19 is very rare. The aim of this study is to know the prognosis and evaluate the management of therapy in thalassemia β Mayor patients with COVID-19. This case study describes the progression of Thalassemia β Mayor with COVID 19 starting from how to establish the diagnosis of Thalassemia β Mayor and COVID 19 until how to treat thalassemia β Mayor patients with COVID-19 This case study result describes that COVID 19 aggravates thalassemia β Mayor. Infection can adversely affect thalassemia. Giving Blood transfusions must be done due to anemia in Thalassemia, but it will have an impact on the accumulation of iron in the body which will increase the severity of the infection. The administration of iron-chelation drugs is beneficial for Covid but on the other hand, it is contraindicated in Thalassemia patients.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Case Report</style></work-type><accession-num><style face="normal" font="default" size="100%">27</style></accession-num><section><style face="normal" font="default" size="100%">445</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Yosua Butar Butar&lt;sup&gt;1,*&lt;/sup&gt;, Puspa Wardhani&lt;sup&gt;2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;F1Clinical Pathology Specialist Medicine Academic Program, Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo General Regional Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Airlangga University/Dr. Soetomo General Regional Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>